A practical reference on fatty diacid: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
=== EC 1.14.19 With oxidation of a pair of donors resulting in the reduction of O2 to two molecules of water === EC 1.14.19.1: stearoyl-CoA 9-desaturase EC 1.14.19.2: stearoyl-[acyl-carrier-protein] 9-desaturase EC 1.14.19.3: linoleoyl-CoA desaturase EC 1.14.19.4: acyl-lipid (11-3)-desaturase EC 1.14.19.5: acyl-CoA 11-(Z)-desaturase EC 1.14.19.6: acyl-CoA (9+3)-desaturase EC 1.14.19.7: Now EC 1.11.1.23, (S)-2-hydroxypropylphosphonic acid epoxidase EC 1.14.19.8: pentalenolactone synthase EC 1.14.19.9: tryptophan 7-halogenase EC 1.14.19.10: icosanoyl-CoA 5-desaturase EC 1.14.19.11: acyl-[acyl-carrier-protein] 4-desaturase EC 1.14.19.12: acyl-lipid ω-(9-4) desaturase EC 1.14.19.13: acyl-CoA 15-desaturase EC 1.14.19.14: linoleoyl-lipid Δ9 conjugase EC 1.14.19.15: (11Z)-hexadec-11-enoyl-CoA conjugase EC 1.14.19.16: linoleoyl-lipid Δ12 conjugase (11E,13Z-forming) EC 1.14.19.17: sphingolipid 4-desaturase EC 1.14.19.18: sphingolipid 8-(E)-desaturase EC 1.14.19.19: sphingolipid 10-desaturase EC 1.14.19.20: Δ7-sterol 5(6)-desaturase EC 1.14.19.21: cholesterol 7-desaturase EC 1.14.19.22: acyl-lipid ω-6 desaturase (cytochrome b5) EC 1.14.19.23: acyl-lipid (n+3)-(Z)-desaturase (ferredoxin) EC 1.14.19.24: acyl-CoA 11-(E)-desaturase EC 1.14.19.25: acyl-lipid ω-3 desaturase (cytochrome b5) EC 1.14.19.26: acyl-[acyl-carrier-protein] 6-desaturase EC 1.14.19.27: sn-2 palmitoyl-lipid 9-desaturase EC 1.14.19.28: sn-1 stearoyl-lipid 9-desaturase EC 1.14.19.29: sphingolipid 8-(E/Z)-desaturase EC 1.14.19.30: acyl-lipid (8-3)-desaturase EC 1.14.19.31: acyl-lipid (7-3)-desaturase EC 1.14.19.32: palmitoyl-CoA 14-(E/Z)-desaturase EC 1.14.19.33: Δ12 acyl-lipid conjugase (11E,13E-forming) EC 1.14.19.34: acyl-lipid (9+3)-(E)-desaturase EC 1.14.19.35: sn-2 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.36: sn-1 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.37: acyl-CoA 5-desaturase EC 1.14.19.38: acyl-lipid Δ6-acetylenase EC 1.14.19.39: acyl-lipid Δ12-acetylenase EC 1.14.19.40: hex-5-enoyl-[acyl-carrier protein] acetylenase EC 1.14.19.41: sterol 22-desaturase EC 1.14.19.42: palmitoyl-[glycerolipid] 7-desaturase EC 1.14.19.43: palmitoyl-[glycerolipid] 3-(E)-desaturase EC 1.14.19.44: acyl-CoA (8-3)-desaturase EC 1.14.19.45: sn-1 oleoyl-lipid 12-desaturase EC 1.14.19.46: sn-1 linoleoyl-lipid 6-desaturase EC 1.14.19.47: acyl-lipid (9-3)-desaturase EC 1.14.19.48: tert-amyl alcohol desaturase EC 1.14.19.49: tetracycline 7-halogenase EC 1.14.19.50: noroxomaritidine synthase EC 1.14.19.51: (S)-corytuberine synthase EC 1.14.19.52: camalexin synthase EC 1.14.19.53: all-trans-retinol 3,4-desaturase EC 1.14.19.54: 1,2-dehydroreticuline synthase EC 1.14.19.55: 4-hydroxybenzoate brominase (decarboxylating) EC 1.14.19.56: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] chlorinase EC 1.14.19.57: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] brominase EC 1.14.19.58: tryptophan 5-halogenase EC 1.14.19.59: tryptophan 6-halogenase EC 1.14.19.60: 7-chloro-L-tryptophan 6-halogenase EC 1.14.19.61: dihydrorhizobitoxine desaturase EC 1.14.19.62: secologanin synthase EC 1.14.19.63: pseudobaptigenin synthase EC 1.14.19.64: (S)-stylopine synthase EC 1.14.19.65: (S)-cheilanthifoline synthase EC 1.14.19.66: berbamunine synthase EC 1.14.19.67: salutaridine synthase EC 1.14.19.68: (S)-canadine synthase EC 1.14.19.69: biflaviolin synthase EC 1.14.19.70: mycocyclosin synthase EC 1.14.19.71: fumitremorgin C synthase EC 1.14.19.72: (–)-pluviatolide synthase EC 1.14.19.73: (S)-nandinine synthase EC 1.14.19.74: (+)-piperitol/(+)-sesamin synthase EC 1.14.19.75: very-long-chain acyl-lipid ω-9 desaturase EC 1.14.19.76: flavone synthase II EC 1.14.19.77: plasmanylethanolamine desaturase EC 1.14.19.78: decanoyl-[acyl-carrier protein] acetylenase
Static self-assembly is significantly slower compared to dynamic self-assembly as it depends on the random chemical interactions between particles. Self assembly can be directed in two ways. The first is by manipulating the intrinsic properties which includes changing the directionality of interactions or changing particle shapes. The second is through external manipulation by applying and combining the effects of several kinds of fields to manipulate the building blocks into doing what is intended. To do so correctly, a high level of direction and control is required and developing a simple, efficient method to organize molecules and molecular clusters into precise, predetermined structures is crucial.
== External links == PL-6983 for Sexual Dysfunction - Palatin Technologies PL-6983 for Female Sexual Dysfunction - Palatin Technologies Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi How Medicines Work To Improve Potency - Vera Farmacia
intein Any sequence of one or more amino acids within a precursor polypeptide that is excised by protein splicing during post-translational modification and is therefore absent from the mature protein, analogous to the introns spliced out of RNA transcripts. Contrast extein.
Knowing Nixon's fears, Kissinger told him that if he did nothing, "it shows that you're weak, Mr. President. The fact that some idiot can publish all the diplomatic secrets of this country on his own is damaging to your image as far as the Soviets are concerned and it could destroy our ability to conduct foreign policy". Daniel Ellsberg, the man who leaked the Pentagon Papers to the New York Times, had been consulted by Kissinger for ideas about Vietnam in late 1968–early 1969, but when he leaked the papers, Kissinger told Nixon that he was a left-wing "fanatic" and a "drug abuser". Kissinger depicted Ellsberg to Nixon as a drug-crazed, sexually perverted degenerate of questionable mental stability out to ruin his administration. Reflecting his increasing frustration with the war, Nixon often talked to Kissinger in a bloodthirsty manner about a "fantasy holocaust" in which he would have U.S. forces kill every living thing in North Vietnam and then pull out, leading the latter appalled by his own account. By early 1972, Nixon boasted that he had pulled out 400,000 U.S. soldiers from Vietnam since July 1969, and battle deaths had fallen from an average of 200 per week in 1969 down to an average of 10 per week in 1972. The policy of Vietnamization had, as Laird predicted, tamed the antiwar movement as most Americans objected not to the war in Vietnam per se, only to Americans dying in it.
Sources: en.wikipedia.org
== Names == Alternative terms for low level light therapy are: LLLT, laser biostimulation, laser phototherapy, low-level laser therapy, low-power laser irradiation, low-power laser therapy, and photobiomodulation therapy. The term photobiomodulation therapy is considered the preferred term by industry professionals. However LLLT has been marketed and researched under a number of other terms, including red light therapy, low-power laser therapy (LPLT), soft laser therapy, low-intensity laser therapy, low-energy laser therapy, cold laser therapy, bio-stimulation laser therapy, photo-biotherapy, therapeutic laser, and monochromatic infrared light energy (MIRE) therapy. More specific applications sometimes have their own terms, for example when administered to acupuncture points, the procedure is called laser acupuncture. When applied to the head, LLLT may be known as transcranial photobiomodulation, transcranial near-infrared laser therapy (NILT), or transcranial low level light therapy.
== Consumption == Worldwide sugar provides 10% of the daily calories (based on a 2000 kcal diet). In 1750 the average Briton got 72 calories a day from sugar. In 1913 this had risen to 395. In 2015, sugar still provided around 14% of the calories in British diets. According to one source, per capita consumption of sugar in 2016 was highest in the United States, followed by Germany and the Netherlands.
Mad honey intoxication is a result of eating honey containing grayanotoxins. Honey produced from flowers of rhododendrons, mountain laurels, sheep laurel, and azaleas may cause honey intoxication. Symptoms include dizziness, weakness, excessive perspiration, nausea, and vomiting. Less commonly, low blood pressure, shock, heart rhythm irregularities, and convulsions may occur, with rare cases resulting in death. According to the FDA, honey intoxication is more likely when using "natural" unprocessed honey from farmers who may have a small number of hives because commercial processing, which pools of honey from numerous sources, dilutes the toxins. Toxic honey may also result when bees are proximate to tutu bushes (Coriaria arborea) and the vine hopper insect (Scolypopa australis). Both are found throughout New Zealand. Bees gather honeydew produced by the vine hopper insects feeding on the tutu plant. This introduces the poison tutin into honey. Only a few areas in New Zealand (the Coromandel Peninsula, Eastern Bay of Plenty Region and the Marlborough Sounds) frequently produce toxic honey. Symptoms of tutin poisoning include vomiting, delirium, giddiness, increased excitability, stupor, coma, and violent convulsions. To reduce the risk of tutin poisoning, humans should not eat honey taken from feral hives in the risk areas of New Zealand. Since December 2001, New Zealand beekeepers have been required to reduce the risk of producing toxic honey by closely monitoring tutu, vine hopper, and foraging conditions within 3 km (2 mi) of their apiary.
=== Reverence === In some pre-industrial societies, semen and other body fluids were revered because they were believed to be magical. Blood is an example of such a fluid, but semen was also widely believed to be of supernatural origin and effect and was, as a result, considered holy or sacred. The ancient Sumerians believed that semen was "a divine substance, endowed on humanity by Enki", the god of water. The semen of a god was believed to have magical generative powers. In Sumerian mythology, when Enki's seed was planted in the ground, it caused the spontaneous growth of eight previously nonexistent plants. Enki was believed to have created the Tigris and Euphrates rivers by masturbating and ejaculating into their empty riverbeds. The Sumerians believed that rain was the semen of the sky-god An, which fell from the heavens to inseminate his consort, the earth-goddess Ki, causing her to give birth to all the plants of the earth. The orchid's twin bulbs were thought to resemble the testicles, which is the etymology of the disease orchiditis. There was an ancient Roman belief that the flower sprang from the spilled semen of copulating satyrs. In a number of mythologies around the world, semen is often considered analogous to breast milk. In the traditions of Bali, it is considered to be the returning or refunding of the milk of the mother in an alimentary metaphor. The wife feeds her husband who returns to her his semen, the milk of human kindness.
== Overall survival == For incident dialysis patients (mean age ~65 years), median survival is about 3 years, with adjusted mortality rates of 187.7 per 1,000 patient-years. 1-year survival: 80–85% overall; 60–70% for patients ≥65 years. 3-year survival: ~57% for HD, ~68% for peritoneal dialysis (PD). 5-year survival: 35–42% for HD; PD outcomes converge long-term.
Sources: en.wikipedia.org
During this period, Aden became important for British military and commercial purposes in the region, as well as a base for the Royal Navy and the Royal Air Force. The colony's surrounding hinterland, was governed separately as the Aden Protectorate. By the early 1960s, widespread dissatisfaction with British rule led to the Aden Emergency, a violent uprising against colonial authorities. In 1963, Aden Colony was reconstituted as the State of Aden within the newly created Federation of South Arabia in an attempt to grant limited self-governance, but the unrest continued. The British withdrew in 1967, and the colony was succeeded by the People's Republic of Southern Yemen, marking the end of British control after 128 years of rule.
=== Phrixotoxin-1 === Mice that are injected with phrixotoxin-1 can experience numerous, transient, adverse cardiac reactions, such as premature ventricular beats, ventricular tachycardia, and atrio-ventricular blocks. Neurological effects observed are motor impairment and convulsions. These effects are seen following both intravenous and intracisternal injection, making it likely that phrixotoxin-1 crosses the blood brain barrier (Diochot 1999).
=== Disappearance === On 4 March 1998, at around 2:00 PM, Mendonça took his bicycle and cycled to his mother's workplace, located near the family home. He had asked his mother for permission to spend the afternoon riding in a car "with his friend Afonso" (Afonso Dias), a 22-year-old lorry driver. Mendonça's mother denied the request, and told him to go play in an abandoned lot outside her office.
== Calcitonin gene-related peptide receptor == Agonists: Amylin CGRP Pramlintide Antagonists: Atogepant BI 44370 TA CGRP (8-37) MK-3207 Olcegepant Rimegepant SB-268262 Telcagepant Ubrogepant Antibodies: Eptinezumab Erenumab Fremanezumab Galcanezumab
Ivermectin/albendazole is indicated for use in people aged five years of age or older, for the treatment of soil-transmitted helminth infections, caused by different types of intestinal parasitic worms, which are spread through soil contaminated by human feces in areas with poor sanitation. Among the worms responsible for these diseases are hookworms (Ancylostoma duodenale, Necator americanus), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura) and a roundworm called Strongyloides stercoralis. Ivermectin/albendazole is also indicated for the treatment of microfilaraemia (the presence of worm larvae in the blood) in people with lymphatic filariasis. Lymphatic filariasis is a neglected tropical disease commonly known as elephantiasis, which impairs the lymphatic system and can lead to the abnormal enlargement of body parts, causing pain, severe disability and social stigma. Ivermectin/albendazole is indicated for the treatment of cases of lymphatic filariasis caused by Wuchereria bancrofti, a parasite which is responsible for 90% of cases worldwide.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.